Ms. Lana Culley reports

AURORA CANNABIS ANNOUNCES BREAKTHROUGH DISCOVERY OF POWDERY MILDEW RESISTANT CULTIVARS

Aurora Cannabis Inc. has discovered a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew-resistant cultivars that will be explored for commercial launch this year.

"This discovery offers a critical solution to a pressing challenge in the cannabis industry worldwide. At Aurora Coast, our state-of-the-art research-and-development facility, we continuously search for ways to add value to our proprietary cannabis cultivars, and this discovery will lead to new means of managing disease in cannabis production. This success story underscores the impact of our investment in scientific excellence, a commitment that sets Aurora apart from our competitors," says Lana Culley, vice-president of innovation and international operations at Aurora.

In the peer-reviewed research lead by Jose Celedon, principal scientist of breeding and genetics at Aurora, in collaboration with researchers at the University of British Columbia, it is noted that, "breeding genetic resistance to economically important crop diseases is the most sustainable strategy for disease management and enhancing agricultural and horticultural productivity, particularly where the application of synthetic pesticides is prohibited." The discovery of PM2 will further the company's mission to enhance the biosecurity of production facilities, reduce production costs and improve product quality.

As a global medical cannabis company enabled by science, Aurora's dedication to scientific research and innovation has led to remarkable advancements, notably boosting potency and yield. These improvements have overall reduced costs and increased efficiency. This cutting-edge genetic research and development differentiates Aurora from others in the industry, as it aims to surpass traditional breeding limitations, leading to advanced cultivation methods and new market opportunities worldwide.

This discovery has also been protected via international patent filings.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora has brands that continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

We seek Safe Harbor.